FXR activation has been reported to reduce renal overexpression of SREBP-1 and lipogenic enzymes as well as decreasing lipid accumulation in mouse models of diabetes (65) and obesity (60), thereby acting to reduce profibrotic factors. The gene discussed is SREBF1; the disease is obesity disorder.